Mast cells are critical immune effectors abundant in tissues interfacing with the environment and have major roles in allergen-induced inflammation and host responses to infection. SCF is a regulator of mast cell function and growth. However, the critical mechanisms in SCF-directed events remain incompletely defined. Here, we have investigated the role of MKK3 in mast cell SCF signaling-dependent functions by using BMMCs from MKK3-deficient mice. MKK3 was phosphorylated rapidly and persistently following SCF-induced activation and contributed to mast cell proliferation but not survival or migration in response to SCF. Analysis of SCF-induced mast cell mediator secretion demonstrated that IL-6 production is specifically dependent on MKK3 signals, both independently and in concert with IgE. Analysis of SCF-induced signaling showed that sustained p38 phosphorylation was impaired in MKK3-deficient mast cells, wheras early JNK and IB␣ activation were enhanced. Notably, SCF-inducible expression and activation of c-Jun, a component of the AP-1 transcription factor, was significantly dependent on MKK3. Accordingly, AP-1 DNA-binding activity and interaction with the IL6 gene promoter was markedly impaired in MKK3-deficient mast cells, whereas transcription factors of the Egr family, NF-B, and NFAT retained near-full activity. These results designate MKK3 as a novel, positive regulator of SCF-induced mast cell proliferation and a critical signaling protein for AP-1-dependent IL-6 production. J. Leukoc. Biol. 95: 903-915; 2014.
Introduction
Mast cells are abundant at diverse tissue sites that interface with the environment and have emerged as key regulators of innate and acquired immunological processes, in addition to their well-known role in allergy [1] [2] [3] . Acting as local armouries, mast cells are packed with preformed mediators, primed for release in immediate responses, and are also capable of rapid and inducible production and secretion of a broad array of important mediators, including cytokines and chemokines. Mast cells originate from progenitors in the bone marrow and are the only terminally differentiated hematopoietic cells that continually express a high level of the receptor for SCF, the tyrosine kinase c-kit (CD117) [4, 5] . Mast cells are critically dependent on SCFmediated c-kit signaling, and the absence of normal c-kit signals results in severe mast cell deficiency [6] . SCF-mediated signals via c-kit are required for growth and survival of tissue-resident mast cells [7] but also contribute to normal and pathological (i.e., allergy) mast cell functional responses [8 -10] . In a physiological scenario, these responses occur frequently in the context of local SCF-c-kit signals, highlighting the importance of appreciating the role of ckit-dependent signals. However, our understanding of mast cell c-kit signaling mechanisms remains incomplete, and the specific contributions of many downstream molecules are unclear.
Activation of mast cells via c-kit initiates an array of signaling pathways, including the MAPK pathway, a complex, three-tiered series of substrate-specific signaling proteins [11, 12] . The MAPK family includes subgroups p38, ERK, and JNK. Specific MAPK activation is controlled by upstream MKKs, which generally act on specific MAPKs. MKK3 (or Map2k3) is a well-known activator of the p38 MAPK in a host of contexts and with diverse cellular outcomes [13] . The resultant impact of signals through the MAPK pathway is generally at the gene-expression level, as targeted downstream transcription factors become activated [14] . Our group has previously described the role of MKK3 as a critical regulator of allergic inflammation via specific control of Egr1-dependent IL-4 production in IgE-dependent mast cell responses [15] , but its role in c-kit signaling has not been investigated previously.
In this study, we demonstrated for the first time that MKK3 is a component in SCF-dependent c-kit signaling. MKK3 is phosphorylated rapidly following SCF stimulation and is required for sustained p38 MAPK activation. MKK3-deficient BMMCs displayed a SCF dose-dependent impairment of proliferation in vitro and a specific and significant defect in SCF-induced IL-6 production. Notably, no contribution was detectable in the potentiation of IL-4 production, highlighting a distinct role for MKK3 in c-kit versus FcRI signaling. Whereas SCF-inducible NF-B, NFAT, and Egr transcriptional activity was not altered markedly in the absence of MKK3, a significant impairment of induced c-Jun protein expression and corresponding AP-1 transcription factor activity was detected. A specific defect in AP-1 binding to the promoter of the IL6 gene was detected following mast cell SCF-mediated activation. These findings position MKK3 as a novel contributor to SCF-induced and AP-1-dependent mast cell IL-6 production through regulation of c-Jun expression.
MATERIALS AND METHODS

Animals
MKK3 knockout mice were generated as described previously [16] and obtained from The Jackson Laboratory (Bar Harbor, ME, USA; B6.129S1-Map2k3 tm1Flv /J). The protocols were approved by the University Committee on Laboratory Animals, Dalhousie University, in accordance with the guidelines of the Canadian Council on Animal Care.
Antibodies
Antibodies to phospho-MKK3/6, phospho-p38 MAPK (Thr 180/Tyr 182), phospho-JNK (Thr 183/Tyr 185), JNK, phospho-ERK1/2, ERK, phospho-c-Jun (Ser63 and Ser73), c-Jun, phospho-Tyr, c-kit, phospho-IB␣, and IB␣ were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies to MKK3, p38 MAPK, actin, and HRP-linked secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Mast cell culture and activation
Mouse primary-cultured BMMCs were cultured as described previously [17] . Mast cells were confirmed routinely by toluidine blue staining and flow cytometry analysis for c-kit and IgER expression (FACSAria I; BD Biosciences, Mississauga, ON, Canada), as described previously. Following 5-6 weeks in culture, mast cell purity was Ͼ98%. For c-kit-mediated activation, BMMCs were stimulated with 100 ng/ml SCF (PeproTech, Dollard des Ormeaux, QC, Canada). For IgE-mediated activation, BMMCs were passively sensitized overnight with TNP-specific IgE from TIB-141 cells (American Type Culture Collection, Manassas, VA, USA), and the following day, unbound IgE was removed by washing cells with RPMI 1640 before resuspending cells in complete BMMC media. Cells were then activated by stimulation with 10 ng/ml TNP-BSA (Biosearch Technologies, Novato, CA, USA). For all experiments, the number of mice/genotype used for BMMC generation is equivalent to the n shown in the figure legends, unless otherwise indicated.
Thymidine incorporation
BMMCs (WT and MKK3-deficient) were seeded at 1 ϫ 10 5 cells/well in triplicate on a 96-well plate. Cells were stimulated with SCF at concentrations of 50 or 100 ng/ml or left untreated for 24 h. In the final 3 h, cells were pulsed with 1 Ci 3 H-thymidine (Perkin Elmer, Montreal, QC, Canada) and harvested to glass filter paper. Incorporation was measured on a Wallac 1409 scintillation ␤ counter.
Cell-cycle analysis
BMMCs were washed in RPMI 1640, starved in 0.2% BSA-RPMI with antibiotics for 4 h, and resuspended in RPMI with 10% FBS and antibiotics (no Wehi/IL-3). Cells were then cultured with 100 ng/ml SCF for 24 h, and cell-cycle staging was conducted using Vybrant DyeCycle Green (Invitrogen, Carlsbad, CA, USA) by flow cytometry (FACSAria I), according to the manufacturer's instructions. Data were analyzed using WinList 5.0 software.
Survival assays
BMMCs were washed and resuspended in RPMI 1640 with 0.2% BSA and antibiotics, with or without various concentrations of SCF for 24 h. Cells were then stained with FITC-Annexin V and 7-AAD for 15 min at room temperature and analyzed by FACS to measure the percent of remaining live cells. beled ( 32 P) dsDNA probe, dried on filter paper for 2 h at 80°C, and finally exposed to BioMax film (Kodak). Probes for AP-1 and NF-B were purchased from Promega (Madison, WI, USA). Probes for Egr and NFAT were as described previously [15] . The AP-1 probe in the mouse IL-6 promoter was the following double-stranded sequence: 5=-GCTCAAGTGCTGAGT-CACTTTTAA-3=. In competition assays, a 100-fold excess of unlabeled probe was added and preincubated with nuclear proteins before addition of the radiolabeled probe. For supershift antibody-blocking assays, 2 g c-Jun antibody (Santa Cruz Biotechnology) was preincubated for 1 h with nuclear proteins. The AP-1 activity assay was from Active Motif and was conducted according to the manufacturer's instructions. Nuclear protein (2 g) was used in the assay with JunD and FosB antibodies. Plates were read at 450 nm to assess activity.
Luciferase assays
WT and MKK3-deficient BMMCs (4ϫ10 6 ) were cotransfected with 3 g luciferase plasmid and 1 g control plasmid (pRL-TK; Promega) using a mouse T cell nucleofector kit (Amaxa; Lonza, Allendale, NJ, USA) and the Amaxa nucleofector device (Program U-023). Luciferase plasmids used include phospho-NFAT-Luc plasmid and phospho-NFB-Luc (Agilent Technologies, Mississauga, ON, Canada). After electroporation, BMMCs were plated in culture medium and allowed to recover for 48 h. Subsequently, cells were stimulated with 100 ng/ml SCF for 6 h. Firefly and Renilla activities were sequentially quantified using a dual-luciferase reporter assay system (Agilent Technologies). Electroporation of BMMCs resulted in ϳ50% cell death with a final overall transfection efficiency of 12.5-20%.
Statistical analysis
The paired Student's t-test was used for statistical evaluation of data. Results were considered significant when P Ͻ 0.05. Data are expressed as means Ϯ sem, except where noted.
RESULTS
MKK3 is phosphorylated rapidly and persistently following mast cell activation by SCF
Engagement and cross-linking of the c-kit receptor by SCF results in intracellular signaling events that contribute to mast cell activation. These signaling events involve members of the MAPK pathway, but the significance of specific components remains incompletely defined. To determine whether MKK3 is activated following SCF stimulation, BMMCs from WT mice were used in an in vitro culture system. To assess MKK3 phosphorylation kinetics following SCF-c-kit signaling, BMMCs were stimulated with 100 ng/ml rSCF, and cell lysates were prepared to assess protein phosphorylation by Western blot. MKK3 was phosphorylated rapidly by 5-min post-SCF treatment, and this activation persisted for up to 120 min (Fig. 1A) . The activation kinetics of the MKK3 downstream substrate, p38 MAPK, mirrored that of MKK3, with rapid and persistent phosphorylation over the stimulation time course (Fig. 1A) . To assess the duration of MKK3 activation following SCF treatment, we examined BMMCs stimulated over a longer period of time, in which the level of MKK3 phosphorylation increased steadily, peaking at 12 h, and gradually fell to near-basal levels by 72 h (Fig. 1B) . These novel results indicate that MKK3 is a contributor to SCF-mediated signaling events in mast cells and prompted an investigation into the significance of MKK3 activity in mast cell SCF-dependent functions.
MKK3 contributes to SCF-induced proliferation but is independent of c-kit receptor phosphorylation, internalization, and degradation dynamics, as well as mast cell survival and migration
To investigate a role for MKK3 in mast cell SCF-c-kit signaling, we cultured BMMCs from WT and MKK3-deficient mice and used these cells to characterize the impact of MKK3 in SCF-dependent mast cell activation. We have previously characterized the normal maturation and expression of c-kit on BMMCs from MKK3-deficient mice [15] . Following SCF interaction and cross-linking, activated c-kit becomes internalized and degraded, influencing the duration and potency of c-kit signaling following mast cell activation [18 -20] . To examine c-kit phosphorylation and degradation, cell lysates were prepared, representing a time course of SCF activation, and Western blots were conducted using antibodies directed at total c-kit and phosphorylated tyrosine to measure overall c-kit phosphorylation. Data for phosphorylation ( Fig. 1C ) and degradation ( Fig. 1D ) were quantified over three independent experiments, and a representative blot is shown (Fig. 1E ). Overall, both activation and degradation of the c-kit receptor appeared to proceed unaltered in the absence of MKK3 ( Fig. 1C-E) . To examine c-kit internalization dynamics in the absence of MKK3, samples of WT and MKK3-deficient BMMCs were collected at various timepoints post-SCF stimulation and analyzed by flow cytometry to quantify surface expression of c-kit. Following stimulation, c-kit internalization proceeded rapidly and continued over time with 65-70% of the detected receptor internalized by 60 min. In addition, MKK3 deficiency did not alter the internalization dynamics of the c-kit receptor (Fig. 1F) . Together, these results indicate that MKK3 does not play a role in the upstream events required for normal c-kit signaling and suggest that in the absence of MKK3, c-kit signaling and processing proceed in a normal manner.
SCF is an important contributor to mast cell survival, proliferation, and migration. To assess the role of MKK3 on SCFmediated mast cell survival, BMMCs were cultured in serumfree media with decreasing concentrations of SCF and at 24 h, were assessed for survival by Annexin V and 7-AAD staining and subsequent FACS analysis to quantify remaining live cells. No significant SCF-mediated distinction was detectable between WT and MKK3-deficient BMMC survival, although MKK3-deficient BMMCs displayed some enhanced survival in the absence of SCF (Fig. 1G) . To assess the impact of MKK3 on SCF-induced mast cell proliferation, WT and MKK3-deficient BMMCs were cultured for 24 h in the presence of 50 or 100 ng/ml SCF, and proliferation was measured by thymidine incorporation. A dose-dependent enhancement in BMMC proliferation was detected, and a mild but statistically significant impairment was observed in MKK3-deficient BMMCs (Fig.  1H) . To determine if MKK3 deificency contributed to delayed cell-cycle kinetics, BMMCs were treated with 100 ng/ml SCF in the absence of IL-3 for 24 h, and cell-cycle staging was assessed by flow cytometry. A robust entry into the S-phase and minimally detectable G 2 /M-phase was detected and quantified, but no difference was detectable between WT and MKK3-deificent 
MKK3 is required specifically for SCF-induced mast cell IL-6 production
The production and secretion of cytokines and chemokines are major effector functions for mast cells with critical roles in innate and acquired immunity, yet the contribution of mediators in distinct downstream mechanisms remains incompletely defined. To examine the role of MKK3 in SCF-induced mast cell cytokine production, a time course of cell-free culture supernatants from WT and MKK3-deficient BMMCs stimulated with SCF was prepared and analyzed by ELISA. Induction of IL-6, IL-13, TNF, and CCL2 was detectable following SCF stimulation ( Fig. 2) , but only IL-6 production was impaired consistently and significantly in samples from MKK3-deficient BMMCs ( Fig. 2A) . IL-4 and IL-5 were undetectable in SCFstimulated BMMCs. These results suggest that MKK3 is a medin ϭ 3 independent experiments is shown. (B) WT BMMCs were treated with SCF for various times, spanning 72 h, and phosphorylation of MKK3 was monitored by Western blot, quantified by densitometry analysis relative to total MKK3 and expressed as means Ϯ sem for n ϭ 3 independent experiments. (C-E) Phosphorylation and degradation of c-kit were assessed in WT and MKK3-deficient BMMCs, stimulated with SCF over a time course by Western blot. Data for phospho-Tyr c-kit (C) and total c-kit (D) were quantified by densitometry analysis and presented as means Ϯ sem.
Representative blots for n ϭ 3 independent experiments are shown (E). (F) WT and MKK3-deficient BMMCs were treated with SCF over a time course in serum-free conditions, and cells were assessed for cell-surface expression of c-kit by flow cytometry. Data are expressed as the average Ϯ sem of percent mean fluorescence intensity for untreated cells, for n ϭ 3 independent experiments. (G) WT and MKK3-deficient BMMCs were cultured in serum-free RPMI 1640 with decreasing concentrations of SCF for 24 h, then stained with FITC-Annexin V and 7-AAD, and were analyzed by FACS to measure remaining live cells. Data are expressed as percent survival Ϯ sem for n ϭ 3 independent experiments. (H) WT and MKK3-deficient BMMCs were stimulated with 50 or 100 ng/ml SCF or left untreated for 24 h. Cells were pulsed with 3 H-thymidine in the final 3 h, incorporation was measured (CPM), and data were expressed as fold-change from untreated cells Ϯ sem for n ϭ 10 independent experiments using BMMCs from five mice/genotype. *P Ͻ 0.05. (I) WT and MKK3-deficient BMMCs were cultured in RPMI 1640 with 10% FBS in the absence of IL-3 and stimulated with 100 ng/ml SCF for 24 h. Cells were then stained with Vybrant DyeCycle Green (FITC) and analyzed by flow cytometry to assess cell-cycle changes. Data are expressed as percent cells in S ϩ G 2 /M phases Ϯ sem for n ϭ 3 independent experiments. NT, Not treated. (J) Transwell migration assays were conducted with WT and MKK3-deficient BMMCs in the upper chamber and 10 ng/ml SCF in the lower chamber. After 4 h, the total migrated cell number was counted, and data are expressed as means Ϯ sem for n ϭ 6 independent experiments using BMMCs from three mice/genotype. WT and MKK3-deficient BMMCs (2ϫ10 6 /ml), in complete BMMC media, were stimulated with 100 ng/ml SCF for the indicated times or left untreated, and cell-free culture supernatents were collected and analyzed for induced IL-6 (A), IL-13 (B), TNF (C), and CCL2 (D) production following stimulation by ELISA. Data are expressed as means Ϯ sem for n ϭ 6 independent experiments. **P Ͻ 0.01; ***P Ͻ 0.001.
ator of SCF-induced events specific to the production of IL-6 by mast cells.
SCF-dependent potentiation of IgE-mediated mast cell cytokine production remains intact in the absence of MKK3
Mast cells have a well-known and central role in allergy [3] . During allergic events, mast cells, sensitized with FcRIbound, allergen-specific IgE, are activated following allergen exposure and produce an array of cytokines that perpetuate allergic inflammation. Physiologically, allergen-dependent mast cell activation takes place in the context of many other extracellular signaling ligands, including local SCF. Fc⑀RI and c-kit signals proceed via overlapping mediators, meaning that local SCF can potentiate mast cell IgE-dependent responses, thereby enhancing mast cell mediator production further [10] . It is important to note that we have previously examined the role of mast cell MKK3 in allergic inflammation and determined that in the context of Fc⑀RI signaling, mast cell MKK3 is required specifically for IL-4 production. To examine the significance of MKK3 in SCF-dependent potentiation of mast cell cytokine production, WT and MKK3-deficient BMMCs were sensitized with TNP-specific IgE and then stimulated with TNP-BSA to achieve activation via Fc⑀RI, in conjunction with SCF over a time course or in the absence of SCF. Increased production of IL-6, TNF, and CCL2 was detectable by BMMCs stimulated through both receptors, with a consistent impairment of IL-6 detectable (Fig. 3A, C, and D) . However, the fold-change enhancement of IL-6 production at 24 h, relative to cells stimulated with IgE only, was 1.6-fold for WT and 1.8-fold for MKK3-deficient BMMCs, indicating that despite a statistical difference in total IL-6 production, the actual fold-change enhancement of IgE-mediated IL-6 production, as a result of SCF, remains intact in the absence of MKK3. Interestingly, whereas IL-4 production was impaired, as expected in MKK3-deficient BMMCs stimulated through Fc⑀RI, no enhancement of IL-4 production was detectable by stimulation through both receptors (Fig. 3B) . These results strongly suggest that MKK3 has distinct roles in mast cell cytokine production, dependent on receptor-specific signaling events (SCF-c-kit vs. IgE-Fc⑀RI) that proceed via distinct mechanisms. In addition, these results support a role for MKK3 in SCF-potentiated mast cell IL-6 production in allergic inflam- 
MKK3 suppresses SCF-induced mast cell IB␣ phosphorylation but does not influence NF-B or NFAT transcription factor activity
The NF-B and NFAT family transcription factors are major contributors to mast cell cytokine production in a variety of contexts and can cooperate with other transcription factors to enhance gene expression [21, 22] . To examine the role of MKK3 in regulation of the NF-B pathway in SCF-activated mast cells, Western blot analysis of IB␣ activity was conducted and revealed an enhancement of IB␣ activation ( Fig. 4A and  B) . IB␣ inhibits NF-B in the cytoplasm and upon activation, is degraded, releasing NF-B for nuclear translocation and promotion of gene expression. To examine BMMC SCF-induced NF-B activity directly, EMSA analysis was conducted but indicated similar activity in WT and MKK3-deficient BMMCs (Fig. 4C ). Analysis of NFAT activity was also examined by EMSA and suggested little variation between WT and MKK3-deficient BMMCs (Fig. 4D ). To examine these two transcription factors further, a luciferase reporter assay was conducted by transfecting BMMCs with NF-B and NFAT-dependent luciferase reporter plasmids and activating these cells by stimulation with SCF, but no significant difference was detectable in the case of either ( Fig. 4E and F) . These results suggest that neither NF-B nor NFAT is significantly dependent on MKK3 in SCF-induced mast cell activation.
MKK3 is required for full SCF-induced p38 MAPK activity in mast cells and is inhibitory to JNK MAPK activation
To investigate the downstream MAPK signaling events dependent on MKK3, cell lysates were prepared from WT and MKK3-deficient BMMCs over a time course of SCF stimulation to analyze the phosphorylation of the MAPK proteins. Following SCF stimulation, early (5 min), p38 phosphorylation was unaltered in BMMCs, but 40 -120 min post-stimulation, a significant defect in p38 activity was detected in MKK3-deficient cells ( Fig. 5A and B) . In addition, whereas induced ERK activity was not markedly altered in the absence of MKK3, JNK activity from 5 to 20 min was enhanced significantly (Fig. 5C-F) . These results suggest that following the initial spike in p38 activity induced upon SCF stimulation, MKK3 is required to maintain increased p38 activity over time. These results also point to an inhibitory role for MKK3 in early JNK activation downstream of c-kit.
MKK3 is required for c-Jun expression and AP-1 transcriptional activity on the IL-6 promoter following SCF-mediated activation but does not affect Egr activity
Coordinated signaling through the MAPK pathway is critically important in the activation of an array of transcription factors that facilitates the de novo transcription of many important mast cell-secreted cytokines. In mast cells activated through IgE-Fc⑀RI signaling, we have shown that MKK3 is required specifically for the induced activity of Egr1 on the promoter of the IL4 gene via p38 [15] . Meanwhile, JNK is a well-known kinase of the c-Jun component of the AP-1 transcription factor [23] . We investigated the induction of several families of transcription factors following mast cell activation with SCF, including the Egr and AP-1 types. To investigate c-Jun activation, we conducted Western blot analysis of lysates from SCF-stimulated BMMCs and found that despite enhanced JNK activity, c-Jun phosphorylation at Ser63 and Ser73 was actually impaired (Fig. 6A) . However, upon investigation of the level of total protein, we detected a significant impairment of SCF-induced c-Jun protein in MKK3-deficient BMMCs (Fig. 6A and  B) . These results suggest that MKK3 plays a positive role in the induction of c-Jun expression following SCF-mediated mast cell activation.
To follow up on this result, we conducted EMSA to assess the transcription factor activity of AP-1 in SCF-activated mast cells. Nuclear proteins from WT and MKK3-deficient BMMCs were assessed for AP-1 DNA-binding activity using a labeled consensus dsDNA probe over a time course of SCF stimulation. Induced AP-1 DNA binding was detectable in WT BMMCs, peaking near 60 min post-stimulation, and a dramatic defect in AP-1 activity was observed in MKK3-deficient cells (Fig. 6C) . The specificity of the AP-1 probe binding was confirmed by blocking with an unlabeled probe in a competition assay, and importantly, the direct contribution of c-Jun was confirmed by blocking with anti-c-Jun antibodies using a supershift assay (Fig. 6D) . To examine AP-1 transcriptional activity further in SCF-activated BMMCs, an AP-1 activity assay was conducted using nuclear proteins isolated in a time course of SCF stimulation, which demonstrated impaired induction of AP-1 activity in MKK3-deficient cells, supporting the EMSA result (Fig. 6E) . AP-1 has known functions in the promotion of IL-6 expression [24 -26] . To address more specifically whether AP-1 can contribute to IL-6 expression in SCF-activated mast cells, a dsDNA probe consisting of an AP-1 binding site in the IL6 promoter was created and used in EMSA. This analysis demonstrated that induced AP-1 can indeed bind to the promoter of the IL6 gene following SCF treatment in mast cells and that this binding is impaired when cells are deficient for MKK3 (Fig. 6F) .
To investigate the Egr transcription factors, EMSA analysis was conducted with a labeled Egr consensus-binding probe. Unlike the impairment that we have described previously for MKK3-deficient BMMCs activated by IgE [15] , no marked deficiency in Egr activity was observed (Fig. 6G) . This finding suggests that MKK3-dependent Egr activity in mast cells is not a general mechanism and does not extend to the SCF-c-kit pathway, highlighting a distinction in MKK3-dependent signaling via Fc⑀RI versus c-kit. Altogether, these results suggest that MKK3 makes a specific contribution to mast cell SCF-induced c-kit signaling to promote c-Jun expression and ultimately, AP-1 transcription factor activity on the IL6 promoter, supporting a mechanism driving and/or enhancing locally activated mast cell IL-6 production, as shown in our proposed model (Fig. 7) . 
DISCUSSION
Mature tissue resident mast cells are inseparably linked to the local cytokine milieu to which they are sensitive, not only for homeostatic control of growth and survival but also during mast cell activation-dependent functional responses and mediator release [10] . SCF is a relatively abundant cytokine that has been shown to play an important role in modulating mast cell responses through interaction with a membrane-bound c-kit receptor. Normal serum SCF concentrations are in the nanogram range (1-5 ng/ml) [27] , which can be locally enhanced by secretion from endothelial cells, fibroblasts, and monocytes, for example [28] . Despite its important role in potentiating and/or attenuating mast cell responses in various contexts, the intracellular c-kit signaling molecules that regulate specific mast cell mediator secretion remain incompletely defined. The aim of this study was to determine the significance of c-kit signaling through the downstream dual-specificity kinase MKK3 in activated mast cells. Our results are the first to describe MKK3 phosphorylation and activation following c-kit-mediated signaling. With the use of an in vitro MKK3-deficient mast cell-culture system, we identify a role for MKK3 in SCF-induced proliferation and an IL-6-specific role in SCFinduced cytokine production, both independently and in concert with IgE-Fc⑀RI-dependent mast cell signaling. MKK3-deificent mast cells displayed defective p38 MAPK signaling following SCF treatment and had a significantly impaired induction of c-Jun expression, resulting in a major defect in inducible AP-1 transcription factor activity. AP-1 was shown to bind inducibly the promoter of the IL6 gene following SCF treatment, mechanistically linking defective mast cell IL-6 production to MKK3-dependent induction of c-Jun/AP-1.
Our finding here-that MKK3 has a specific role in IL-6 production when mast cells were activated with SCF-was particularly intriguing given our previous findings in the context of allergic-inflammatory, IgE-dependent signaling, wherein a specific defect in IL-4 production was detected [15] . Together, these findings highlight unique roles for MKK3-dependent signaling in distinct but similar mast cell signaling pathways. This was suggestive of a mechanistic distinction in the resultant downstream signaling events through MKK3 in each respective context, which was confirmed upon investigation. Whereas IgE-mediated IL-4 production relied significantly on the MKK3-dependent induction of Egr1 transcription factor activity on the IL4 gene promoter, no major defect in Egr1 activity was detectable in MKK3-deficient mast cells stimulated with SCF. These findings suggest that MKK3 makes distinct, mechanistic contributions to inducible gene expression in the context of c-kit and Fc⑀RI mast cell signaling, driving c-Jun or Egr1 expression, respectively, and resulting in the production and secretion of differing cytokines with important mast cell-dependent roles in a host of inflammatory physiological contexts from infection to allergy.
A role for MKK3-dependent signals in IL-6 production has been reported in models of rheumatoid arthritis [29, 30] , in which cultured fibroblasts of the joint synovium exhibit defective IL-6 production when stimulated with TNF or IL-1␤. However, mechanistic work showed that TNF-induced and MKK3-dependent IL-6 production in these cells was NF-B-depenScanning densitometry analysis of c-Jun expression relative to actin. *P Ͻ 0.05. (C) To assess c-Jun function, nuclear proteins from WT and MKK3-deficient BMMCs were analyzed for AP-1 transcription factor activity by EMSA using a consensus dsDNA probe. A representative gel from n ϭ 2 independent experiments is shown. (D) To assess binding specificity to the AP-1 probe, competition and antibody-blocking experiments were performed, including unlabeled probe in 100-fold excess and preincubation with 2 g c-Jun antibody. (E) Nuclear protein from WT and MKK3Ϫ/Ϫ BMMCs, stimulated with 100 ng/ml SCF for various indicated times, was assessed using an AP-1 activity assay. Data are presented as Ϯ sem for n ϭ 4 independent experiments. *P Ͻ 0.05; **P Ͻ 0.01. (F) To look specifically at AP-1 binding to the IL-6 promoter in SCF-stimulated BMMCs, EMSA was conducted using a dsDNA probe composed of a predicted AP-1-binding site in the IL-6 promoter. A representative gel from n ϭ 2 independent experiments is shown. (G) Egr transcription factor activity was examined by EMSA in WT and MKK3Ϫ/Ϫ BMMCs, stimulated with SCF. A representative gel from n ϭ 2 independent experiments is shown. 
